Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications

NCT05827614 is registered in ClinicalTrials.gov with Boundless Bio, Inc. as lead sponsor.

NCT NCT05827614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05827614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications
Lead sponsor
Boundless Bio, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
March 24, 2023
Completion date
March 17, 2026
Enrollment
85 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

anogenital cancer, cervical squamous cell carcinoma, cutaneous squamous cell carcinoma (cscc), er+ breast cancer, head and neck (hnscc), high grade endometrial carcinoma, high grade serous ovarian carcinoma, leiomyosarcoma (lms), pancreatic cancer metastatic, small cell lung cancer, triple negative breast cancer (tnbc), undifferentiated pleomorphic sarcoma (ups)